Investigating how Sema3C signaling affects Wnt signaling in glioblastoma
Official title: Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11072044 · Data updated 2026-11-12
This study is looking at how a protein called Sema3C affects brain cancer cells and their growth, with the hope of finding better treatments that work alongside current therapies to help patients with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $402,500 |
| NIH project number | 5R01NS130798-03 |
| Project ID | NIH-11072044 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel therapeutic approaches targeting the Wnt signaling pathway.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with glioblastoma may not receive any benefit from this research.
What this research studies
This research explores the role of Sema3C signaling in glioblastoma, particularly how it activates the Wnt signaling pathway, which is often disrupted in various cancers. The study aims to understand the mechanisms behind this activation and how it contributes to the growth and survival of glioma stem-like cells. By using mouse models, the researchers will assess the potential of targeting Sema3C signaling to enhance the effectiveness of existing Wnt inhibitors, which have shown limited success in clinical trials. This could lead to the development of new therapeutic strategies with reduced toxicity for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for glioblastoma patients.
How similar studies have gone: While the approach of targeting Wnt signaling is being explored, the specific role of Sema3C in this context is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Yu, Jennifer S — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Yu, Jennifer S
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.